 |
市場調查報告書
商品編碼
1615989
二肽基肽酶 4 抑制劑市場機會、成長動力、產業趨勢分析和 2024 年至 2032 年預測Dipeptidyl Peptidase 4 Inhibitors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032 |
||||||
2023 年，全球二肽基肽酶 4 抑制劑市場估值為 113 億美元，預計在預測期內複合年成長率為 3.5%。市場擴張主要是由於全球 2 型糖尿病盛行率不斷上升，增加了對有效治療方法的需求。 DPP-4 抑制劑正在成為治療第 2 型糖尿病的首選，因為它們能夠調節血糖水平，而不會引起體重增加或低血糖等明顯副作用。這些抑制劑的作用是防止荷爾蒙分解，從而刺激胰島素釋放以響應進餐。
藥物開發和新配方的進步也促進了市場的成長。製藥公司正致力於開發具有更好功效和安全性的 DPP-4 抑制劑，並透過更持久的配方等創新來提高患者的依從性。聯合療法也出現了新的趨勢，其中包括 DPP-4 抑制劑和其他抗糖尿病藥物，從而提供更全面的血糖管理方法。從藥物類型來看，市場分為沙格列汀、西他列汀、利格列汀、阿格列汀、維格列汀等。
2023年，西他列汀佔最大市場佔有率，佔40.4%。其在管理血糖方面的悠久歷史，加上其廣泛的可用性和成熟的品牌影響力，有助於鞏固其主導地位。市場按藥物類型進一步分類，包括品牌 DPP-4 抑制劑和學名藥 DPP-4 抑制劑。到 2023 年，品牌藥物市場價值 79 億美元，由於支持品牌藥物有效性和安全性的廣泛臨床試驗，該市場處於領先地位。
| 市場範圍 | |
|---|---|
| 開始年份 | 2023年 |
| 預測年份 | 2024-2032 |
| 起始值 | 113 億美元 |
| 預測值 | 152 億美元 |
| 複合年成長率 | 3.5% |
此細分市場受益於強大的分銷網路以及醫療保健提供者和患者之間的信任。就分銷管道而言，市場分為醫院藥房、零售藥房和網路藥房。由於對糖尿病專業護理的需求不斷成長，醫院藥房預計將以 3.4% 的複合年成長率成長。北美在全球市場中佔據主導地位，到2023 年將達到46 億美元。年成長率成長。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 2 型糖尿病盛行率上升
- 患者對口服藥物的高度偏好
- 聯合治療趨勢增加
- 產業陷阱與挑戰
- 其他抗糖尿病藥物的可用性
- DPP-4 抑制劑相關的副作用
- 成長動力
- 成長潛力分析
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按藥物類型，2021 - 2032
- 主要趨勢
- 西格列汀
- 沙格列汀
- 利格列汀
- 阿格列汀
- 維格列汀
- 其他藥物類型
第 6 章：市場估計與預測：按藥物類型，2021 - 2032 年
- 主要趨勢
- 品牌化
- 通用的
第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥局
- 網路藥局
第 8 章：市場估計與預測：按地區分類，2021 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 9 章：公司簡介
- AstraZeneca plc
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novartis AG
- Pfizer, Inc.
- Takeda Pharmaceuticals Company Limited
- Sanofi
- Sanwa Kagaku Kenkyusho Co., Ltd.
The Global Dipeptidyl Peptidase 4 Inhibitors Market was valued at USD 11.3 billion in 2023 and is expected to grow at a CAGR of 3.5% during the forecast period. The market expansion is largely driven by the increasing prevalence of type 2 diabetes worldwide, boosting demand for effective treatments. DPP-4 inhibitors are becoming a preferred choice for managing type 2 diabetes due to their ability to regulate blood sugar levels without causing significant side effects such as weight gain or hypoglycemia. These inhibitors work by preventing hormones' breakdown, which stimulates insulin release in response to meals.
Advancements in drug development and new formulations are also contributing to the market's growth. Pharmaceutical companies are focusing on creating DPP-4 inhibitors that offer better efficacy and safety, with innovations like longer-lasting formulations to improve patient adherence. There is also an emerging trend toward combination therapies that include DPP-4 inhibitors alongside other antidiabetic drugs, offering a more comprehensive approach to managing blood sugar. In terms of drug types, the market is divided into saxagliptin, sitagliptin, linagliptin, alogliptin, vildagliptin, and others.
In 2023, sitagliptin held the largest market share, accounting for 40.4%. Its long history of effectiveness in managing blood glucose, combined with its wide availability and established brand presence, has helped solidify its dominance. The market is further categorized by medication type, with branded and generic DPP-4 inhibitors. The branded segment was worth USD 7.9 billion in 2023 and leads the market due to extensive clinical trials supporting the efficacy and safety of branded drugs.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $11.3 Billion |
| Forecast Value | $15.2 Billion |
| CAGR | 3.5% |
This segment benefits from strong distribution networks and trust among healthcare providers and patients. When it comes to distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are expected to grow at a CAGR of 3.4%, driven by the increasing need for specialized diabetes care. North America dominated the global market, accounting for USD 4.6 billion in 2023. The region's market is projected to grow at a 3.4% CAGR, fueled by the rising incidence of type 2 diabetes, high obesity rates, and well-established healthcare infrastructure, especially in the U.S., where demand for DPP-4 inhibitors continues to rise.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of type 2 diabetes
- 3.2.1.2 High patient preference for oral medications
- 3.2.1.3 Increasing combination therapy trend
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Availability of other antidiabetic drugs
- 3.2.2.2 Side effects associated with DPP-4 inhibitors
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Sitagliptin
- 5.3 Saxagliptin
- 5.4 Linagliptin
- 5.5 Alogliptin
- 5.6 Vildagliptin
- 5.7 Other drug types
Chapter 6 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Branded
- 6.3 Generic
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacies
- 7.3 Retail pharmacies
- 7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AstraZeneca plc
- 9.2 Bristol Myers Squibb Company
- 9.3 Boehringer Ingelheim International GmbH
- 9.4 Eli Lilly and Company
- 9.5 Merck & Co., Inc.
- 9.6 Mitsubishi Tanabe Pharma Corporation
- 9.7 Novartis AG
- 9.8 Pfizer, Inc.
- 9.9 Takeda Pharmaceuticals Company Limited
- 9.10 Sanofi
- 9.11 Sanwa Kagaku Kenkyusho Co., Ltd.
